The right drug targets for the right patient – Using biomarkers to solve challenges in drug development

selectscience

Protein biomarkers provide a dynamic and powerful approach to identify and understand novel drug targets in early in drug development. The pharmaceutical industry utilizes biomarkers to help uncover disease progression markers, responder signatures, diagnostic biomarkers, and potential new indications.

Leading experts will:

  • Share their opinions on how biomarkers can help drive early clinical phase trials
  • Discuss their work with biomarkers at present
  • Explore the history of protein biomarkers within their organization
  • Predict how the field will evolve to meet future challenges

Key learning objectives

From this webinar, you will gain an understanding of the challenges and solutions behind the use of protein biomarkers in drug discovery, and appreciate the use of protein biomarker solutions for patient stratification by disease severity.

Presenters

Dr. Jürgen Braunger, Head of Cellular and Protein Biomarkers, Boehringer Ingelheim

Timothy Radstake MD, PhD, Executive Director Immunology Discovery & Distinguished Research Fellow Head Transformational and Translational Immunology Discovery (TTID), AbbVie

Dr. Christopher D. Whelan, Associate Director of Computational Biology, Biogen

Moderator: Dr. Matthew McArdle, Editor, SelectScience

2947

Biomarker assays

~475 million

Protein data points generated

662

Publications listed on website

35

Certified Core Labs

Contact us!